Transarterial radioembolisation combined with targeted therapy and immune checkpoint inhibitors in advanced hepatocellular carcinoma with portal vein tumour thrombus: efficacy, safety, and dosimetric analysis
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8372-8385
DOI: 10.1007/s00259-026-08143-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 21.08.2026. Verfasst von Weifu Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Ch…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Radioembolization, Therapeutic, Portal Vein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT) carries a dismal prognosis. This study evaluated the efficacy and safety of transarterial radioembolisation (TARE) combined with targeted therapy and immune checkpoint inhibitors (ICIs) in patients with HCC and Vp2-Vp4 PVTT, and explored the tumour absorbed dose (TAD) threshold associated with survival benefit. METHODS: We retrospectively analysed 31 patients with HCC and Vp2-Vp4 PVTT treated with this triplet regimen. Tumour responses were assessed per mRECIST and RECIST 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The optimal TAD cutoff was identified through dose-threshold exploration and internally validated by bootstrap resampling. RESULTS: The objective response rate was 77.4% per mRECIST and 54.8% per RECIST 1.1 (P = 0.023), with a disease control rate of 93.5%. Median PFS and OS were 10.0 months (95% CI, 7.9-NR) and 16.4 months (95% CI, 9.1-NR), respectively. Grade ≥ 3 treatment-related adverse events occurred in 22.6% of patients; no treatment-related death occurred. Exploratory analysis identified TAD ≥ 140 Gy as independently associated with improved PFS after multivariable adjustment (HR = 0.33, 95% CI, 0.11-0.95; P = 0.039), with a concordant trend for OS. Bootstrap validation confirmed robustness. CONCLUSION: TARE combined with targeted therapy and ICIs demonstrates encouraging efficacy with an acceptable safety profile in advanced HCC with Vp2-Vp4 PVTT. TAD ≥ 140 Gy was associated with improved survival, providing a hypothesis-generating basis for personalised dosimetric optimisation in future prospective trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
- Fujian Provincial Key Laboratory of Tumor Biotherapy, Fuzhou, China.
- Department of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. ywc21jy@163.com.
- Fujian Provincial Key Laboratory of Tumor Biotherapy, Fuzhou, China. ywc21jy@163.com.
Zitieren
APA
Liu, W., Fang, Z., Hao, M., Hu, Y., Chen, S., Zhang, K., Wang, X., Chen, Z., & Yu, W. (2026). Transarterial radioembolisation combined with targeted therapy and immune checkpoint inhibitors in advanced hepatocellular carcinoma with portal vein tumour thrombus: efficacy, safety, and dosimetric analysis. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8372-8385. https://doi.org/10.1007/s00259-026-08143-3
Vancouver
Liu W, Fang Z, Hao M, Hu Y, Chen S, Zhang K, et al. Transarterial radioembolisation combined with targeted therapy and immune checkpoint inhibitors in advanced hepatocellular carcinoma with portal vein tumour thrombus: efficacy, safety, and dosimetric analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8372-8385. doi:10.1007/s00259-026-08143-3
BibTeX
@article{Liu2026,
author = {Liu, Weifu and Fang, Zhuting and Hao, Mingzhi and Hu, Yubin and Chen, Shiguang and Zhang, Kongzhi and Wang, Xiaolong and Chen, Zhangxian and Yu, Wenchang},
title = {Transarterial radioembolisation combined with targeted therapy and immune checkpoint inhibitors in advanced hepatocellular carcinoma with portal vein tumour thrombus: efficacy, safety, and dosimetric analysis},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8372--8385},
doi = {10.1007/s00259-026-08143-3}
}
EUVIMED